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ABSTRACT Amyloid ﬁbrils found in various neurodegenerative disorders are also recognized as high-performance protein
nanomaterials with a formidable rigidity. Elucidation of an underlyingmolecular mechanism of the amyloid ﬁbril formation is crucial
not only to develop controlling strategy toward the diseases, but also to apply the protein ﬁbrils for future nanobiotechnology.
a-Synuclein is an amyloidogenic protein responsible for the radiating ﬁlament formation within Lewy bodies of Parkinson’s
disease. The amyloid ﬁbril formation of a-synuclein has been shown to be induced from the oligomeric granular species of
the protein acting as a growing unit by experiencing structural rearrangement within the preformed oligomeric structures in the
presence of an organic solvent of hexane. This granule-based concerted amyloid ﬁbril formation model would parallel the
prevalent notion of nucleation-dependent ﬁbrillation mechanism in the area of amyloidosis.
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Amyloidosis is a clinical condition in which amyloid fibril
formation derived from once soluble and innocuous proteins
serves for a pathological signature as observed in various
neurodegenerative disorders including Alzheimer’s disease,
Parkinson’s disease (PD), and Prion disease (1–3). The amy-
loid fibrils have been also recognized as high-performance
protein nanomaterials with a formidable rigidity (4,5). Eluci-
dation of underlying molecular mechanism for the fibril for-
mation, therefore, would provide us with not only controlling
strategies toward the amyloidosis-related disorders but also
biomaterials for future applications in the area of nano-
biotechnology. The nucleation-dependent fibrillation has
been widely recognized as a prevalent mechanism (6,7). By
acting template, the nucleation centers accrete monomeric
soluble proteins to the insoluble product of fibrils by directing
structural transformation. In this article, however, we show
an alternative fibrillation mechanism of concerted granular
assembly to support the so-called stepwise polymerization
model. a-Synuclein is an amyloidogenic protein responsible
for the radiating filament formation in Lewy bodies of PD (8).
Three separate missense mutations (A30P, E46K, and A53T)
of its gene found in familial PD and deficits inmotor activities
of transgenic animals overexpressing the protein support the
pathological role of a-synuclein (9,10). After a prolonged
incubation in vitro, the protein known to exist in a ‘natively
unfolded’ state turns into amyloid fibrils with discrete b-sheet
conformation (11,12). Despite a great deal of effort, however,
molecular mechanism for the fibril formation and toxic
identity responsible for the neurodegeneration have not been
unambiguously unveiled. In this respect, oligomeric species
of a-synuclein have garnered much attention to assess not
only the toxic cause but also the fibrillation process. The olig-
omeric species have been suggested to be a transient inter-
mediate observed on the way to the eventual fibril formation
(6,11). Alternatively, those species were also considered as an
off-pathway product independent of the fibrillation process
(13,14). From the pathological point of view, they are sug-
gested to be a toxic culprit for the neuronal degeneration by
affecting membrane stability. We try to show that the oligo-
meric granular species act as a growing unit for the amyloid
fibril formation by experiencing structural rearrangement
within the preformed oligomeric structures in the presence of
an organic solvent of hexane.
Accelerated amyloid fibril formation was observed with
the oligomeric structures of a-synuclein in the presence of
hexane (Fig. 1). The granular intermediates were collected at
12-h point during the lag phase of the fibrillation kinetics in
which the stationary phase was reached in more than 60 h of
prolonged incubation with a continuous shaking (Fig. 1 A).
Homogeneous granular structures were revealed under atomic
force microscope (AFM) with average height and width of
4.08 nm and 51.65 nm, respectively (see the Supplementary
Material, Data S1). Dynamic light scattering experiment
provided a hydrodynamic diameter of 49.04 nm for the
granules (see the Supplementary Material, Data S1). The
oligomeric species still retained mostly random structure as
determined with circular dichroism spectroscopy although the
minimum ellipticity at 195 nm became noticeably increased
from that of soluble monomeric a-synuclein (Fig. 1 B). As
hexane was added to a final concentration of 3%, the
granules impressively turned into discrete amyloid fibrils
within mere 5 min of vortexing. Shorter fibrils started to
appear from 1% as shown with both AFM and transmission
electron microscope (TEM) (Fig. 1, C and D). At 10%
hexane, however, amorphous protein aggregates were
obtained. On the other hand, the solvent did not affect the
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monomeric protein at any concentrations to 10% (Fig. 1 E).
The hexane-induced fibril was indistinguishable from the
agitation-induced fibril obtained at the stationary phase (Fig.
1 A) with respect to their rugged surface appearance (Fig.
2 A). Its saw-like surface structure may indicate that the
fibrillation could be derived from lateral association among the
preformed granular species as they are structurally distorted
or altered by the solvent. As a matter of fact, our ANS
binding study showed that the granular species experienced
a significant structural rearrangement as the ANS binding
fluorescence at 475 nm was enhanced (Fig. 2 B, middle)
whereas the ANS binding to monomeric a-synuclein was not
influenced by the hexane treatment (Fig. 2 B, left).
To assess the granular assembly process, the preformed
oligomeric species were incubated in the presence and ab-
sence of 5% hexane, which was compared with another fibril-
lation kinetics obtained by replacing a half of the granules with
monomeric a-synuclein (Fig. 3 A). At the early stages of fibril-
lation (12-h time point), the hexane treatment augmented the
fibrillation of the granule-only (1 mg) preparation by;2-fold
compared to the 1:1 mixture between granules (0.5 mg) and
monomers (0.5 mg), indicating that the hexane-dependent fibril-
lation was proportional to the quantity of granules (Fig. 3 B).
Even after a prolonged incubation, the monomer-containing
granular preparation did not reach to the fibrillation level
achieved by the granule-only preparation regardless of the
presence of hexane (Fig. 3 A). To prove the assembly of gran-
ular units, the 1:1 mixture was subjected to centrifugation to
FIGURE 1 (A) Amyloid ﬁbrillation kinetics of a-synuclein; gran-
ule collection at 12 h (arrow). (B) Circular dichroism spectra of
monomers, granules, and amyloid ﬁbrils. (C) AFM and (D) TEM
imagesof the granules treatedwith hexane at ﬁnal concentrations
shown on the panels. (E) AFM images of the monomers treated
with hexane. Scale bars in AFM and TEM represent 1 mm and
200 nm, respectively.
FIGURE 2 (A) AFM images of hexane- (top) and agitation-
induced (bottom) ﬁbrils; their surface appearance. (B) ANS
binding ﬂuorescence spectra of the monomer, the granule, and
the amyloid in the presence (s) and absence (d) of 5% hexane.
Scale bar, 0.25 mm.
FIGURE 3 (A) Amyloid ﬁbrillation kinetics of a-synuclein pre-
pared in 1:1mixtures of granule1 granule or granule1monomer
in the presence and absence of 5% hexane. (B) Thioﬂavin-T
binding ﬂuorescence of the aggregation mixtures collected at
12 h. (C) Protein content in the supernatants and (D) thioﬂavin-T
binding ﬂuorescence of the precipitates for the 1:1 mixture of
granule 1 monomer with and without the 5% hexane-treatment.
(E) AFM images of the precipitates with (right) and without
hexane (left). Scale bar, 1 mm.
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separate supernatant and precipitate in the presence or ab-
sence of the hexane treatment at 5%. Monomer level was
evaluated in the supernatant with BCA protein assay whereas
the fibril formation was monitored with thioflavin-T binding
fluorescence and AFM. The monomer level in the hexane-
treated sample was 0.83 mg/ml that was very much comparable
to the amount obtained without the hexane treatment (Fig. 3C).
The precipitate contained a considerable level of amyloid fibrils
as judged by the thioflavin-T binding fluorescence along with
the AFM image (Fig. 3, D and E). In the absence of hexane,
however, no fibrils except the granules were found in the
precipitate(Fig. 3 E). Taken together, the amyloid fibrils have
been shown to be produced exclusively from the granules
without any involvement of the monomeric species.
In the presence of hexane, the amyloid fibrils were pro-
duced from the preformed granules, not from the monomers,
through the structural distortion/alteration imposed by the
organic solvent (Scheme 1). Subsequent lateral association of
the energized granular species is responsible for the final
suprastructure formation. Therefore, a concerted association
mechanism of the preformed oligomeric species of a-synuclein
has been proposed, in which the structural distortion induced
by hexane could be considered as a prerequisite for the
accelerated amyloid fibril formation. Exposure of the inter-
faces previously involved in intramolecular interactions within
the preformed structures would lead to new engagement for
intermolecular interactions between the distorted granules by
acting as a growing unit in the presence of hexane.
Themechanism proposed in this report as the granule-based
concerted amyloid fibril formation would provide a conceptual
framework for which therapeutic strategies could be developed
to take care of various amyloidosis-related diseases. In addition,
the novel assembly mechanism from the preformed granular
structures could shed light on our understanding of supra-
structure formation and producing protein-based nanomate-
rials for applications in the area of biotechnology.
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SCHEME 1 Amyloid ﬁbril formation of a-synuclein in the pres-
ence of hexane.
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